Evidence map›Paper›PMID 39885064›Full record

Trial reportObesity surgery2025

A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass.

Ali Lahooti, Anna C Hoff, Brian Critelli, Amier Hassan, Donevan Westerveld, Kaveh Hajifathalian, Enad Dawod, Cynthia O Akagbosu, Waleed Aljohani, Kamal Hassan and 7 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ali LahootiWeill Cornell Medical College, New York, NY, USA.
Anna C HoffAngioskope Clinic, São José Dos Campos, Brazil.
Brian CritelliWeill Cornell Medical College, New York, NY, USA.
Amier HassanWeill Cornell Medical College, New York, NY, USA.
Donevan WesterveldWeill Cornell Medical College, New York, NY, USA.
Kaveh HajifathalianRutgers New Jersey Medical School, Newark, NJ, USA.
Enad DawodWeill Cornell Medical College, New York, NY, USA.
Cynthia O AkagbosuWeill Cornell Medical College, New York, NY, USA.
Waleed AljohaniWeill Cornell Medical College, New York, NY, USA.
Kamal HassanWeill Cornell Medical College, New York, NY, USA.
Gabriel Cairo NunesAngioskope Clinic, São José Dos Campos, Brazil.
Sergio BarrichelloAngioskope Clinic, São José Dos Campos, Brazil.
Manoel Galvao NetoAngioskope Clinic, São José Dos Campos, Brazil.
Jimi ScarparoAngioskope Clinic, São José Dos Campos, Brazil.
Carolyn NewberryWeill Cornell Medical College, New York, NY, USA.
Sonal KumarWeill Cornell Medical College, New York, NY, USA.
Reem Z SharaihaWeill Cornell Medical College, New York, NY, USA. rzs9001@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransoral outlet reduction endoscopy (TORe) and glucagon-like peptide-1 agonist, liraglutide, have individually shown promise in managing weight regain after Roux-en-Y gastric bypass. However, combined effects of adjunctive liraglutide to TORe remain unexplored. A cross-over design was utilized to evaluate the efficacy of liraglutide treatment when initiated immediately post-TORe or 1 year post-TORe.

methodsData was analyzed from a double-blinded randomized controlled trial conducted at three outpatient clinics in São Paulo, Brazil, from January 2019 to December 2021. Two cohorts were established: group placebo then liraglutide (group PL) received subcutaneous saline dosed daily for 12 months after TORe then liraglutide for the subsequent 12 months, while group liraglutide then placebo (group LP) started subcutaneous liraglutide followed by subcutaneous saline in a similar fashion. Each participant received placebo and liraglutide for equal duration over the 24-month treatment phase. The primary outcomes were percent total body weight loss (%TBWL) at 12 and 24 months.

resultsThe study comprised 58 participants in group PL and 51 participants in group LP, with no significant difference in mean baseline BMI between groups. Group LP showed significantly higher %TBWL than group PL at 6, 9, and 12 months. Surprisingly, at 21 and 24 months, group LP continued to exhibit greater %TBWL than group PL, even after discontinuing liraglutide.

conclusionImmediate post-procedure administration of liraglutide appears to be more effective than placebo in reversing weight regain in patients undergoing TORe. Results indicate that the timing of post-TORe liraglutide initiation may enhance the therapeutic benefits of the procedure.

Indexed as

Gastric BypassGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideNatural Orifice Endoscopic SurgeryObesity, MorbidWeight GainAdultCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeWeight LossGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideBariatric endoscopyGlucagon-like peptide-1 agonistRoux-en-Y gastric bypassTransoral outlet reduction endoscopyWeight regain

Identifiers

PMID39885064

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.